Harbour Capital Advisors LLC Sells 390 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Harbour Capital Advisors LLC lowered its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 6.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,062 shares of the company’s stock after selling 390 shares during the quarter. Harbour Capital Advisors LLC’s holdings in TransMedics Group were worth $430,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of TMDX. NBC Securities Inc. purchased a new stake in shares of TransMedics Group during the 1st quarter worth $25,000. Atlas Capital Advisors Inc. bought a new position in TransMedics Group in the fourth quarter worth about $31,000. AlphaQuest LLC purchased a new stake in shares of TransMedics Group during the fourth quarter valued at about $52,000. Rakuten Securities Inc. lifted its position in shares of TransMedics Group by 68.3% during the fourth quarter. Rakuten Securities Inc. now owns 1,355 shares of the company’s stock valued at $84,000 after buying an additional 550 shares during the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in shares of TransMedics Group by 58.0% in the 4th quarter. Venturi Wealth Management LLC now owns 1,373 shares of the company’s stock valued at $86,000 after buying an additional 504 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Piper Sandler reissued an “overweight” rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Finally, Oppenheimer upped their target price on TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a research report on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $127.33.

TransMedics Group Trading Up 3.2%

NASDAQ TMDX opened at $127.53 on Tuesday. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a fifty day simple moving average of $115.04 and a two-hundred day simple moving average of $84.67. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92. The stock has a market cap of $4.31 billion, a P/E ratio of 93.77 and a beta of 2.10.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The firm’s revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.35 EPS. On average, analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity

In related news, Director Edward M. Basile sold 6,000 shares of the firm’s stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the transaction, the director now owns 732 shares of the company’s stock, valued at $84,641.16. This trade represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David Weill sold 732 shares of the business’s stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the transaction, the director now owns 12,134 shares of the company’s stock, valued at $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,418 shares of company stock valued at $1,512,613. Company insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.